Accueil

La principale fonction du Groupe Dépistage du CIRC consiste à produire des données sur l'exactitude, la reproductibilité, l'efficacité, les avantages, les effets néfastes et la rentabilité de diverses interventions de dépistage précoce pour les cancers du sein, du col utérin, et pour les cancers colorectal et buccal, entre autres, en faisant baisser la mortalité et en améliorant la qualité de vie des patients dans différents contextes. Ces données peuvent ensuite être utilisées pour informer et améliorer l'utilisation rationnelle des ressources de soins de santé. L'objectif ultime du Groupe est de guider l'élaboration de politiques de santé publique pour la mise en œuvre du dépistage dans divers contextes de soins de santé, notamment dans les pays à revenu faible ou intermédiaire (PRFI).

Le Groupe SCR mène des études de terrain dans les PRFI pour évaluer diverses méthodes de détection précoce dans la lutte contre les cancers du sein, du col utérin, et les cancers colorectal et buccal. Ces initiatives visent aussi à identifier la façon dont les services de dépistage pourraient être intensifiés par le biais des services de santé publique au niveau local. Le Groupe développe diverses ressources de formation pour catalyser et renforcer les capacités en étroite collaboration avec les institutions nationales et les services de santé du gouvernement. Grâce à son programme de recherche, le Groupe apporte des bases scientifiques factuelles pour soutenir l'élaboration de politiques de détection précoce et de systèmes de santé appropriés pour la prestation de services primaires efficaces. Par exemple, le Groupe a contribué de manière significative à l'évaluation de l'innocuité et de l'efficacité d’un régime de moins de trois doses du vaccin contre le VPH pour la protection contre le cancer du col de l'utérus.


Actualité

EMERGENCY: Coronavirus disease (COVID-19) Pandemic

16/03/2020
Regular updates on the coronavirus disease (COVID-19) outbreak are available at the WHO website.

The TogetHER Interview: Partha Basu

20/11/2020
The impact of COVID-19 on global cervical cancer prevention efforts has been wide-ranging, with unclear long-term ramifications. The new TogetHER Interview series provides an opportunity for key leaders in global cervical cancer control to discuss current challenges and provide perspective on where the field needs to go from here. This new installment of the TogetHER Interview series features Dr. Partha Basu, Head of the International Agency for Research on Cancer’s Screening Group. View the interview.

CanScreen5 Train the Trainers - Africa Region Live session 4

20/11/2020
Continuation of the CanScreen5 Train the Trainers African course, with participants from 17 African countries. Participants of this training already completed the following e-learning modules: Principle of cancer screening, planning and implementing a cancer screening programme, and quality of cancer screening programme. Today, Dr Sharon Kapambwe, Cancer Assistant Director, Cancer Control, Ministry of Health, Zambia, addressed a key not lecture about the Zambian experience for cervical cancer screening. Learn more about the CanScreen5 platform and the IARC learning platform.

Virtual conference: NCI at London Global Cancer Week 2020

20/11/2020
This virtual conference is organized by the US National Cancer Institute Center for Global Health (CGH) within the London Global Cancer Week 2020. This webinar will showcase examples of global cancer research partnerships and collaborations from the US National Cancer Institute (NCI) perspective. The session will start with an overview of NCI Center for Global Health (CGH) and NCI global health priorities as laid out by CGH Director Satish Gopal, MD, MPH. The session will also include unique viewpoints on building global cancer research collaborations as outlined by NIH-funded cancer researchers and trainees from different regions of the world. The presentations will highlight aspects of partnership-building to advance global cancer research, lessons learned, and recommendations. Dr Partha Basu, Head of Screening Group, Early Detection & Prevention Section at the International Agency for Research on Cancer will discuss about the role of collaborative research to identify effective and affordable technologies and inform global policies in cancer prevention. View more about this virtual conference and free registration.

New publication: Digital atlas of visual inspection of the cervix with acetic acid for screening, triage, and assessment for treatment

17/11/2020
To mark the official launch by the World Health Organization of the Global Strategy to Accelerate the Elimination of Cervical Cancer, the International Agency for Research on Cancer (IARC) is pleased to announce the launch of a new digital atlas, the Atlas of visual inspection of the cervix with acetic acid for screening, triage, and assessment for treatment. The objectives of the new atlas are to describe the use of visual inspection of the cervix with acetic acid (VIA) as a primary screening test or as a test to triage women who test positive for oncogenic human papillomavirus (HPV) types, and to explain how application of dilute acetic acid to the cervix can help in determining eligibility for ablative treatment. View the digital atlas, the IARC news, the IARC page about WHO Global Strategy to Accelerate the Elimination of Cervical Cancer.

Toutes les actualités


Publications scientifiques

Bhatla N., Nessa A., Oswal K., Vashist S., Sebastian P., Basu P. Program organization rather than choice of test determines success of cervical cancer screening: Case studies from Bangladesh and India. Int J Gynaecol Obstet. 2020 Nov 18.
PMID: 33205399
Taghavi K., Rohner E., Basu P., Low N., Rutjes A., Bohlius J. Screening test accuracy of portable devices that can be used to perform colposcopy for detecting CIN2+ in low- and middle-income countries: a systematic review and meta-analysis. BMC Womens Health. 2020 Nov 16;20(1):253.
PMID: 33198721
Kumar S., Khanduri A., Sidibe A., Morgan C., Torode J., Basu P., Bhatla N., Schocken C., Bloem P. Acting on the call: A framework for action for rapid acceleration of access to the HPV vaccination in low- and lower-middle-income countries. Int J Gynaecol Obstet. 2020 Nov 13.
PMID: 33185283

Toutes les publications scientifiques

IARC, 150 Cours Albert Thomas, 69372 Lyon CEDEX 08, France - Tel: +33 (0)4 72 73 84 85 - Fax: +33 (0)4 72 73 85 75
© CIRC 2020 - Terms of use  -  Politique de confidentialité.